<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
        </entity>
        <period>
            <startDate>2026-04-30</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001453687</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-30</startDate>
            <endDate>2026-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-18">0001453687</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="c-1" id="f-19">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:OffsetTableNa contextRef="c-1" id="f-20">N/A</ffd:OffsetTableNa>
    <ffd:FormTp contextRef="c-1" id="f-1">S-8</ffd:FormTp>
    <ffd:SubmissnTp contextRef="c-1" id="f-2">S-8</ffd:SubmissnTp>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Cartesian Therapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="c-2" id="f-4">Equity</ffd:OfferingSctyTp>
    <ffd:PrevslyPdFlg contextRef="c-2" id="f-5">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTitl contextRef="c-2" id="f-6">Common Stock</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c-2" id="f-7">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd contextRef="c-2" decimals="0" id="f-8" unitRef="shares">1040444</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty contextRef="c-2" decimals="3" id="f-9" unitRef="usd">6.915</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric contextRef="c-2" decimals="2" id="f-10" unitRef="usd">7194670.26</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c-2" decimals="8" id="f-11" unitRef="number">0.00013810</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c-2" decimals="2" id="f-12" unitRef="usd">993.58</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="c-1" decimals="2" id="f-13" unitRef="usd">7194670.26</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="c-1" decimals="2" id="f-14" unitRef="usd">993.58</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="c-1" decimals="2" id="f-15" unitRef="usd">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="c-1" decimals="2" id="f-16" unitRef="usd">993.58</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c-2" id="f-17">&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt"&gt;In accordance with Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), this registration statement (this &#x201c;Registration Statement&#x201d;) shall be deemed to cover any additional securities that may from time to time be offered or issued under the Cartesian Therapeutics, Inc. Amended and Restated 2016 Incentive Award Plan (the &#x201c;Incentive Plan&#x201d;) to prevent dilution resulting from stock splits, stock dividends or similar transactions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Consists of 1,040,444 shares of the Registrant&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;) that may become issuable under the Incentive Plan pursuant to its terms.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the Registrant&#x2019;s Common Stock as reported on the Nasdaq Global Market on April 24, 2026.&lt;/span&gt;</ffd:OfferingNote>
</xbrl>
